Integrated BioPharma Reports 19.3% Revenue Decline and Operating Loss for Fiscal Year Ending June 30, 2026

Integrated BioPharma, Inc. reported a significant decline in financial performance for the fiscal year ending June 30, 2026, with net sales dropping to approximately $43.9 million, a decrease of 19.3% from $54.4 million in the previous fiscal year. The decline was primarily attributed to reduced sales from major customers in the Contract Manufacturing Segment, particularly Life Extension Quality Supplements and Herbalife Nutrition, which together accounted for approximately 90% of total sales. The company experienced an operating loss of $2.7 million compared to an operating income of $2.0 million in the prior year, reflecting a substantial shift in profitability.

The decrease in revenue was driven by a $9.3 million drop in the Contract Manufacturing Segment and a $1.2 million decline in Other Business Lines. The company noted that the loss of three significant customers in the Other Business Lines Segment contributed to this downturn. Additionally, profit margins fell sharply from 10.2% in 2025 to 1.8% in 2026, largely due to fixed manufacturing costs remaining stable while sales decreased. Selling and administrative expenses saw a slight reduction of 1.1%, totaling approximately $3.5 million, as the company managed costs amid declining revenues.

Strategically, Integrated BioPharma entered into development and supply agreements with Herbalife International effective January 1, 2026, which will last until December 31, 2028. These agreements are intended to bolster the company's product offerings, although they do not guarantee minimum order quantities. The company continues to focus on maintaining its customer base and exploring opportunities for geographic expansion, primarily in the U.S. and Luxembourg, where most of its customers are located.

As of September 23, 2026, Integrated BioPharma employed approximately 134 full-time staff, with a significant portion covered by a collective bargaining agreement. The company has also transitioned its human resources management to a Professional Employer Organization (PEO) to enhance employee benefits and compliance. Despite the challenges faced in the fiscal year, the company maintains a line of credit of $4 million and a convertible line of credit of $250,000, which it plans to utilize for equipment purchases and operational needs.

Looking ahead, Integrated BioPharma acknowledges the ongoing risks posed by inflation, supply chain disruptions, and regulatory changes that could impact its operations and financial results. The company is committed to adjusting its pricing strategies in response to rising costs while striving to stabilize its revenue streams. Management believes that with its current resources and credit facilities, it can support its working capital requirements through at least September 2027, although the outlook remains cautious given the competitive landscape and economic conditions.